Table 1 Patient characteristics and correction between LND and clinicopathologic variables
Variables | Total | LND1 (< 0.1) | LND2(> = 0.1, < 0.4) | LND3 (> = 0.4) | P value |
|---|---|---|---|---|---|
Patients, n | 4821 | 3170 | 871 | 780 | |
Regional nodes examined | 17.96 ± 12.67 | 17.63 ± 12.64 | 20.02 ± 12.65 | 17.01 ± 12.58 | < 0.001 |
Regional nodes positive | 2.69 ± 5.40 | 0.20 ± 0.57 | 4.27 ± 3.14 | 11.09 ± 8.32 | <0.001 |
Age at diagnosis (years) | 69.73 ± 12.30 | 69.47 ± 11.98 | 70.18 ± 12.65 | 70.24 ± 13.12 | 0.143 |
Sex | 0.291 | ||||
Male | 3075 (63.78%) | 2033 (64.13%) | 536 (61.54%) | 506 (64.87%) | |
Female | 1746 (36.22%) | 1137 (35.87%) | 335 (38.46%) | 274 (35.13%) | |
Year of diagnosis | 0.225 | ||||
2010 | 842 (17.47%) | 536 (16.91%) | 170 (19.52%) | 136 (17.44%) | |
2011 | 816 (16.93%) | 523 (16.50%) | 143 (16.42%) | 150 (19.23%) | |
2012 | 826 (17.13%) | 558 (17.60%) | 138 (15.84%) | 130 (16.67%) | |
2013 | 780 (16.18%) | 500 (15.77%) | 147 (16.88%) | 133 (17.05%) | |
2014 | 800 (16.59%) | 527 (16.62%) | 147 (16.88%) | 126 (16.15%) | |
2015 | 757 (15.70%) | 526 (16.59%) | 126 (14.47%) | 105 (13.46%) | |
Race | 0.229 | ||||
White | 3121 (64.74%) | 2024 (63.85%) | 573 (65.79%) | 524 (67.18%) | |
Asian or Pacific islander | 1019 (21.14%) | 692 (21.83%) | 180 (20.67%) | 147 (18.85%) | |
Black | 629 (13.05%) | 413 (13.03%) | 113 (12.97%) | 103 (13.21%) | |
Other | 52 (1.08%) | 41 (1.29%) | 5 (0.57%) | 6 (0.77%) | |
Marital status at diagnosis | 0.068 | ||||
Married | 2840 (58.91%) | 1900 (59.94%) | 499 (57.29%) | 441 (56.54%) | |
Widowed | 738 (15.31%) | 474 (14.95%) | 140 (16.07%) | 124 (15.90%) | |
Single | 624 (12.94%) | 377 (11.89%) | 126 (14.47%) | 121 (15.51%) | |
Other | 619 (12.84%) | 419 (13.22%) | 106 (12.17%) | 94 (12.05%) | |
Insurance | 0.012 | ||||
Insured | 2950 (61.19%) | 1981 (62.49%) | 526 (60.39%) | 443 (56.79%) | |
Uninsured or unknown | 1871 (38.81%) | 1189 (37.51%) | 345 (39.61%) | 337 (43.21%) | |
Primary site | < 0.001 | ||||
Upper | 1300 (26.97%) | 931 (29.37%) | 230 (26.41%) | 139 (17.82%) | |
Middle | 1433 (29.72%) | 955 (30.13%) | 254 (29.16%) | 224 (28.72%) | |
Lower | 1702 (35.30%) | 1092 (34.45%) | 298 (34.21%) | 312 (40.00%) | |
Overlapping lesion | 386 (8.01%) | 192 (6.06%) | 89 (10.22%) | 105 (13.46%) | |
AJCC stage group, 7th (2010-2015) | < 0.001 | ||||
Stage I | 1910 (39.62%) | 1877 (59.21%) | 27 (3.10%) | 6 (0.77%) | |
Stage II | 1287 (26.70%) | 1010 (31.86%) | 207 (23.77%) | 70 (8.97%) | |
Stage III | 1624 (33.69%) | 283 (8.93%) | 637 (73.13%) | 704 (90.26%) | |
AJCC T, 7th (2010-2015) | <0.001 | ||||
T1 | 1644 (34.10%) | 1539 (48.55%) | 80 (9.18%) | 25 (3.21%) | |
T2 | 708 (14.69%) | 554 (17.48%) | 98 (11.25%) | 56 (7.18%) | |
T3 | 1577 (32.71%) | 829 (26.15%) | 416 (47.76%) | 332 (42.56%) | |
T4 | 892 (18.50%) | 248 (7.82%) | 277 (31.80%) | 367 (47.05%) | |
AJCC N, 7th (2010-2015) | <0.001 | ||||
N0 | 2607 (54.08%) | 2607 (82.24%) | 0 (0.00%) | 0 (0.00%) | |
N1 | 913 (18.94%) | 494 (15.58%) | 317 (36.39%) | 102 (13.08%) | |
N2 | 642 (13.32%) | 67 (2.11%) | 405 (46.50%) | 170 (21.79%) | |
N3 | 659 (13.67%) | 2 (0.06%) | 149 (17.11%) | 508 (65.13%) | |
Grade | <0.001 | ||||
Well differentiated | 515 (10.68%) | 474 (14.95%) | 27 (3.10%) | 14 (1.79%) | |
Moderately differentiated | 1656 (34.35%) | 1243 (39.21%) | 258 (29.62%) | 155 (19.87%) | |
Poorly differentiated | 2570 (53.31%) | 1404 (44.29%) | 577 (66.25%) | 589 (75.51%) | |
Undifferentiated; anaplastic | 80 (1.66%) | 49 (1.55%) | 9 (1.03%) | 22 (2.82%) | |
Chemotherapy | <0.001 | ||||
No/unknown | 3362 (69.74%) | 2434 (76.78%) | 456 (52.35%) | 472 (60.51%) | |
Yes | 1459 (30.26%) | 736 (23.22%) | 415 (47.65%) | 308 (39.49%) | |